Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs
Amount Raised
$12 Million
Round Type
Series A
Plymouth MeetingBiotechnologyHealth CareScience And EngineeringDescription
Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announced today that it has closed its Series A1 round, raising $12 million in financing. The financing was led by Korea Investment Partners (KIP) – Global Bio Fund with strong participation from all existing Series A investors including, notably, Santé Ventures and Inovio Pharmaceuticals, Inc. (NASDAQ: INO). The new investment follows the previously announced initial financing of $10.5 million in February 2019
Quick answer
Geneos Therapeutics raised $12 Million in a Series A round, dated March 3, 2021. Geneos Therapeutics is based in Plymouth Meeting, Pennsylvania, United States.
- How much did Geneos Therapeutics raise?
- Geneos Therapeutics raised $12 Million in a Series A round on March 3, 2021.
- What does Geneos Therapeutics do?
- Geneos Therapeutics, a privately held, clinical stage biotherapeutics company, believes that the company's personalized therapeutic cancer vaccines (PTCVs) may serve an important role in new immunotherapeutic paradigms..
- Where is Geneos Therapeutics based and how big is it?
- Geneos Therapeutics is based in Plymouth Meeting, Pennsylvania, United States.
- Who are the decision-makers at Geneos Therapeutics?
- Fundz holds 2 contacts at Geneos Therapeutics, including the Vice President Head Of Operations Business Development. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Geneos Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Trait Biosciences Inc. raised $12M on March 31, 2021.
- Camp4 Therapeutics Corp raised $15M on March 19, 2021.
- Variantyx raised $20M (Funding Round) on March 15, 2021.
- Viracta Therapeutics raised $65M on March 10, 2021.
- Variantyx raised $16M on March 5, 2021.
- Exscientia raised $100M (Series C) on March 4, 2021.
Who to call at Geneos Therapeutics, and when
A new round usually means Geneos Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Geneos Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Geneos Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Geneos Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Geneos Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansGeneos Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.